Prostate Cancer Specialty Channel

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

Conference Coverage

Talazoparib Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer

03/03/2025

Neeraj Agarwal, MD

Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-2 trial which demonstrated that first-line talazoparib plus enzalutamide improved overall survival among patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses...

03/03/2025

Oncology

Conference Coverage

Mevrometostat Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer

03/03/2025

Michael Schweizer, MD

Michael Schweizer, MD, discusses results from a dose-expansion study which demonstrated that the addition of mevrometostat to enzalutamide improved outcomes among patients with metastatic castration-resistant prostate cancer.

Michael Schweizer, MD, discusses...

03/03/2025

Oncology

Conference Coverage

Addition of Mevrometostat Improves Outcomes for Patients With Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Stephanie Holland

Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.

Results from a dose-expansion...

02/13/2025

Oncology

Conference Coverage

First-Line Talazoparib Plus Enzalutamide Improves Survival for Patients With Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Stephanie Holland

Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.

Results from the phase 3...

02/13/2025

Oncology

Conference Coverage

Addition of Talazoparib to Enzalutamide for HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...

According to results from the...

02/13/2025

Oncology

Conference Coverage

[177Lu]Lu-PSMA-617 Plus Enzalutamide Boosts Survival, Quality of Life for Poor-Risk Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.

The addition of...

02/13/2025

Oncology

News

Sequencing of 177Lu-PSMA-617 and Cabazitaxel Did Not Significantly Impact Survival for Patients With Metastatic Castration-Resistant Prostate Cancer

01/21/2025

Stephanie Holland

According to results from the LuCaS trial, the sequence in which 177Lu-PSMA-617 and cabazitaxel was administered did not significantly impact survival outcomes among patients with metastatic castration-resistant prostate cancer.

According to results from the...

01/21/2025

Oncology

Conference Coverage

First-Line Enzalutamide Plus Ra223 Significantly Improves Radiological PFS in Metastatic Castration-Resistant Prostate Cancer

09/14/2024

Janelle Bradley

Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.

Findings from the phase 3...

09/14/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...

According to long-term results...

05/14/2024

Oncology

News

Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy

04/03/2024

Stephanie Holland

According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...

According to results from the...

04/03/2024

Oncology

News

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the...

03/28/2025

Oncology

Conference Coverage

Talazoparib Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer

03/03/2025

Neeraj Agarwal, MD

Neeraj Agarwal, MD, discusses...

03/03/2025

Oncology

Conference Coverage

Mevrometostat Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer

03/03/2025

Michael Schweizer, MD

Michael Schweizer, MD, discusses...

03/03/2025

Oncology

Conference Coverage

Addition of Mevrometostat Improves Outcomes for Patients With Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Stephanie Holland

Results from a dose-expansion...

02/13/2025

Oncology

Conference Coverage

First-Line Talazoparib Plus Enzalutamide Improves Survival for Patients With Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Stephanie Holland

Results from the phase 3...

02/13/2025

Oncology

Conference Coverage

Addition of Talazoparib to Enzalutamide for HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

According to results from the...

02/13/2025

Oncology

Conference Coverage

[177Lu]Lu-PSMA-617 Plus Enzalutamide Boosts Survival, Quality of Life for Poor-Risk Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.

The addition of...

02/13/2025

Oncology

News

Sequencing of 177Lu-PSMA-617 and Cabazitaxel Did Not Significantly Impact Survival for Patients With Metastatic Castration-Resistant Prostate Cancer

01/21/2025

Stephanie Holland

According to results from the...

01/21/2025

Oncology

Conference Coverage

First-Line Enzalutamide Plus Ra223 Significantly Improves Radiological PFS in Metastatic Castration-Resistant Prostate Cancer

09/14/2024

Janelle Bradley

Findings from the phase 3...

09/14/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results...

05/14/2024

Oncology

Interactive Features

Quiz

Improving Detection of Clinically Significant Prostate Cancer

01/15/2024

True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.

True or False: Adding the...

01/15/2024

Oncology

Quiz

Adjuvant Radiotherapy Following Radical Prostatectomy

11/13/2023

Allison Casey

Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.

Test your knowledge on the...

11/13/2023

Oncology

Quiz

Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.

Test your knowledge with this...

11/10/2023

Oncology

Quiz

Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial

11/10/2023

Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.

Test your knowledge with this...

11/10/2023

Oncology

Quiz

True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.

11/02/2022

True or False: A study found...

11/02/2022

Oncology

Quiz

Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer

09/02/2022

In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...

In the ENZAMET trial evaluating...

09/02/2022

Oncology

Quiz

Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?

07/21/2022

Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?

Quiz: The commercially-available...

07/21/2022

Oncology

Test Your Knowledge

Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?

09/02/2021

True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.

True or false: For patients with...

09/02/2021

Oncology

Test Your Knowledge

Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?

07/29/2021

True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.

True or False: Since small...

07/29/2021

Oncology

Test Your Knowledge

Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?

07/29/2021

Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?

Which treatment approach...

07/29/2021

Oncology

Recent News

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the...

03/28/2025

Oncology

Conference Coverage

Addition of Mevrometostat Improves Outcomes for Patients With Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Stephanie Holland

Results from a dose-expansion...

02/13/2025

Oncology

Conference Coverage

First-Line Talazoparib Plus Enzalutamide Improves Survival for Patients With Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Stephanie Holland

Results from the phase 3...

02/13/2025

Oncology

Conference Coverage

Addition of Talazoparib to Enzalutamide for HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

According to results from the...

02/13/2025

Oncology

Conference Coverage

[177Lu]Lu-PSMA-617 Plus Enzalutamide Boosts Survival, Quality of Life for Poor-Risk Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.

The addition of...

02/13/2025

Oncology

News

Sequencing of 177Lu-PSMA-617 and Cabazitaxel Did Not Significantly Impact Survival for Patients With Metastatic Castration-Resistant Prostate Cancer

01/21/2025

Stephanie Holland

According to results from the...

01/21/2025

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results...

05/14/2024

Oncology

News

Hypofractionated Radiotherapy as Acceptable Treatment Option Post-Prostatectomy

04/03/2024

Stephanie Holland

According to results from the...

04/03/2024

Oncology

News

Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer

02/23/2024

Allison Casey

According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...

According to interim results...

02/23/2024

Oncology

News

PRIMARY Score Superior to MRI for Detecting Clinically Significant Prostate Cancer

01/12/2024

Allison Casey

In a retrospective cohort study, the PRIMARY score was found to be superior to MRI in detecting clinically significant prostate cancer, demonstrating added diagnostic value in patients with negative or equivocal MRI results.

In a retrospective cohort study,...

01/12/2024

Oncology

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology